Skip to content
  • Home
  • Travel
  • Tourism
  • Hotels
  • Event
  • Real Estate
  • Consumer
  • Technology
  • TobuJapanTrip
Menu

eTravel Wire

  • Home
  • Travel
  • Tourism
  • Hotels
  • Event
  • Real Estate
  • Consumer
  • Technology
  • TobuJapanTrip

NRx Pharmaceuticals NRXP: Prominently Featured in Psychiatrist.com; Article Titled "How NRx Could Upend the Fight Against Depression and Suicide"
eTravel Wire/10293201

Trending...
  • New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
  • $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
  • Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
NRXP NASDAQ NRXP 2 NRXP 3 NRXP 4 NRXP 5 Corporate Ads
Substantial Funding Agreements, Debt Resolution and Successful Clinical Trial Progress Towards Accelerated Drug Approval

RADNOR, Pa. - eTravelWire -- NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain

NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

NRx Pharmaceuticals, Inc. Featured on Psychiatrist.com: "How NRx Could Upend the Fight Against Depression and Suicide"

In a high recognition biopharma industry feature, NRXP has been profiled in an article published on Psychiatrist.com.  This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.

The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found at this direct link: https://www.psychiatrist.com/news/how-nrx-could-upend-the-fight-against-depression-and-suicide/.

More on eTravel Wire
  • NR7 Miner launches zero-cost USDT cloud mining service: daily stable income + referral rewards for double profit
  • Deaths Spur Closures, but Troubled Teen Camps Must Be Banned, CCHR Warns
  • Palmer Lake Wine Festival To Build Bridges in Small Mountain Community, Highlight Local Businesses
  • SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
  • From Real Estate to Reel Power: H.L Woods Carves His Legacy as a Cutting-Edge Visionary Filmmaker

The author notes:

"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."

"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."

"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."

Nearly 4 million Americans planned suicide in 2022, with estimates suggesting that two-thirds of cases are associated with a mood disorder.

NRX-101 is an oral, fixed-dose combination of D-cycloserine and lurasidone being developed to treat treatment-resistant bipolar depression with suicidality or akathisia.

NRX-100 is an IV ketamine formulation being studied as a treatment for acute suicidal crises in all forms of depression, including bipolar depression.

The potential of these two NRXP therapies is monumental.  Bipolar disorder presents a significant global health challenge, mostly because of its close ties to higher suicide risk during depressive episodes.  Suicidal Depression affects millions of people every year; a pharmacologic treatment is a critical need.

The lack of FDA-approved pharmacological treatments targeting suicidal and bipolar depression with suicidality or akathisia in today's market underscores the need for more innovative therapies. And, if approved, these new NRXP treatments would be the first FDA-approved pharmaceutical regimens developed to treat these in patients struggling with suicidal behavior, ideation, or depression.

It's not an overstatement to say that NRXP could not only improve the quality of life for millions of people. It would also significantly cut the suicide rates among those affected.

More on eTravel Wire
  • New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
  • Documentary Film "The Story Of Art In Alaska" streaming on Prime Video
  • Orion Retreats: Pioneering the Future of Conscious Leadership and Luxury Wellness Tourism
  • Cynthia Pinot Among Artists Selected for Renowned London Art Biennale 2025
  • Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025

Participation at New York Global Investment Conference

NRXP
has been featured at an important Global Investment Conference held in New York City on September 9-11, 2024.

Investors can listen to the full NRXP presentation via the following link www.hcwevents.com/annualconference

Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics

NRXP
has also announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, NRXP has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. NRXP anticipates potential operations in the United States, France, and the United Kingdom.

This non-dilutive acquisition funding is in addition to the over $60 million in potential equity funding previously offered upon public listing of NRXP spin-off HOPE Therapeutics shares on a public exchange.

To Review $NRXP visit: https://www.nrxpharma.com/ or https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

Media Contact


Company Name: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
Contact Person: Matthew Duffy, Chief Business Officer

Company Website: https://www.nrxpharma.com/
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Home Country: United States

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website

Contact
Corporate Ads
***@gmail.com


Source: Corporate Ads

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on eTravel Wire
  • BK Adventure Announces Wild New Bioluminescent Kayak Tour Near Cocoa Beach
  • AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
  • Construcción del Corredor Norte–Sur (NSC) de Singapur
  • New Report: Slip and Fall Accidents Rank as the Leading Cause of Construction Site Fatalities
  • Get Your Cowboy Boots On! Causeway Country BBQ Music Festival Kicks Off September 12–14 in Ft. Pierce
  • Retired Hobbyist Launches Bold Weekly Album Project Using AI Songwriting Tools
  • DimHum Launches Revolutionary CrowdShipping Service
  • Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
  • Infinite Health Introduces Cutting-Edge Regenerative Medicine for Wound Care with Trip Goolsby, MD
  • Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
  • Bio-Inspired Technology-Dynamic and Adaptable for unknown real-world environments
  • "Retroville RV Park Rolls into Summer with 1960s Drive-In Movie Magic on the Florida Gulf Coast"
  • Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
  • Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
  • $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
  • $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
  • Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
  • Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
  • Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
  • Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
Next Article _docTitle2

Related Posts

_docTitle2

_docDesc2
Read More about _docTitle2

Popular on eTravelWire

  • Advanced Solar Space Technology; Record Efficiency of 15.7%; Agreement to Provide NOVI Space with Rollable PV Array Blankets for Space Launch in 2026 - 226
  • Experience Trembling Firsthand with the New AgeMan® Tremor Simulator - 156
  • AI changes cryptocurrency market trading, TWL Miner launches new 1-day contract, giving away over $1 million - 145
  • DOT Miners launches a new cloud mining platform: low threshold, high transparency, and helps promote the inclusion of global digital assets - 136
  • Lottery.com Inc. Secures $300 Million in Growth Capital, Confirms Nasdaq Compliance & Acquires UAE Sports Incubator Amid High-Profile Brand Exposure - 118
  • United States Congressional Candidate Peter Coe Verbica Unveils 25-Point Federal Plan to Help Make California Affordable Again - 113
  • $750 Million Ketamine Drug Market Withing Reach via New Commissioner's National Priority Vouchers with Anticipated Approval by Year-End for NRx - 109
  • Edtech Startup Young Commanders Launches 'Visionaries Without Sight' Collection Celebrating Blind and Visually Impaired Historical Figures - 107
  • Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI - 105
  • Hamvay-Lang and Lampone.hu Join Forces with AIMarketingugynokseg.hu to Elevate Hungarian Lifestyle Brands on the Global Stage

Similar on eTravelWire

  • Consumer Accountability Alliance Issues Formal Notice Alleging Proximate Liability for Medical Harm
  • NR7 Miner launches zero-cost USDT cloud mining service: daily stable income + referral rewards for double profit
  • Deaths Spur Closures, but Troubled Teen Camps Must Be Banned, CCHR Warns
  • $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
  • West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
  • The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
  • Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
  • Digital Watchdog Launches New myDW Cloud Services
  • AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
  • Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
Theme by Bloompixel. Proudly Powered by WordPress
  • Contribute
  • Terms of Service
  • Privacy Policy
  • Contact Us